UK markets close in 2 hours 55 minutes

HUTCHISON CHINA MEDITECH LTD (0J7G.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
12.76-0.28 (-2.16%)
As of 06:45PM GMT. Market open.
Full screen
Previous close13.04
Open0.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range0.00 - 0.00
52-week range
Volume49
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:​AZN). This milestone has been triggered by the initiation of start-up activities for SAFFRON, the first global Phase III study for ORPATHYS® in combination with TAGRISSO® in epidermal growth factor receptor (“EGFR”)-mutated non-small cell lung cancer (

  • Globe Newswire

    HUTCHMED announces retirement of CEO and appointment of new CEO

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces: (a) the retirement of Mr. Christian Hogg after almost 22 years with the Company, including 15 years as Executive Director and Chief Executive Officer (“CEO”); and(b) the appointment of Dr. Weiguo Su, who has been with the Company for about 17 years, including about 10 years as Chief Scientific Officer (“CSO”) and almost five years as

  • Globe Newswire

    HUTCHMED Reports 2021 Full Year Results and Provides Business Updates

    Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE® growth and the 2021 launches of SULANDA® and ORPATHYS®; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORPATHYS® in lung cancer, kidney and gastric cancer during 2021; Broad late-stage development program – currently enrolling 13 registration studies on 6 assets – with enrollment on the 691 patient FRESCO-2 global Phase III of fruquintinib now complete. Company to Host Annual Results Ca